Appendix II

Table 2 Sample Report for Cosmetics Product Safety Evaluation Report

|  |  |  |  |
| --- | --- | --- | --- |
| **Cosmetics Product Safety Evaluation Report** | | | |
| Title | | Safety evaluation for XXXXX(Product name) | |
| Formula number | |  | |
| Institution | |  | |
| Assessor | |  | |
| Date | |  | |
| ***1. Summary*** | | | |
|  | | | |
|
|
|
| ***2. Characterization*** | | | |
| 1. Name | |  | |
| 2. Formula | | ***Annotation: The function of each ingredient shall be noted.*** | |
| 3. Physiochemical characters of each ingredient | |  | |
| 4. Potential risk substances | |  | |
| 5. Directions | |  | |
| 6. Use purpose or function | |  | |
| 7. Dosage | |  | |
| 8. Others | |  | |
| ***3. Process of Risk Assessment for All Ingredients or Risk Substances*** | | | |
| 1. Hazards Identification | Toxicological Endpoint | 1. Acute Toxicity |  | |
| 2.Irritation/Corrosivity |  | |
| 3.Skin Sensitization |  | |
| 4.Skin Phototoxicity |  | |
| 5.Mutagenicity/Genotoxicity |  | |
| 6. Subchronic Toxicity |  | |
| 7.Reproduction and Growth toxicity |  | |
| 8.Chronic Toxicity/Carcinogenicity |  | |
| 9. Toxicokinetics |  | |
| 10. Crowd Safety Data |  | |
| Hazards Identification |  | |
| 2.Dose-response relationship |  | | |
|
| 3. Exposure assessment |  | | |
| 4. Risk characterization |  | | |
| ***Annotation: Individual risk assessment report is required for all ingredients or risk substances*** | | | |
| ***4. Analysis on risk assessment result*** | | | |
| ***Annotation: The integrity, reliability and scientificity of the information provided and the uncertainty of the data shall be analyzed.*** | | | |
|
|
|
|
| ***5. Risk control measures or suggestions*** | | | |
|  | | | |
|
|
|
| ***6. Safety evaluation conclusion of the finished product*** | | | |
| ***Annotation: Including evaluation results of physiochemical stability, microbiology and human safety data such as clinical data, consumer survey, adverse reaction record and etc.*** | | | |
| ***7. References*** | | | |
| ***Annotation: All related literatures, testing reports andspecification certificate of ingredient shall be included..*** | | | |
|
|
|
|
|
| ***8. Statement*** | | | |
| 1. Cumulative exposure should be concerned in the MoS calculation if two or more ingredients have the same toxicological mechanism. Specific case study is required. | | | |
|
| 2. Additional human patch or trial test should be implemented to prove the product has no local toxicity if the product is manufactured with new product formula ornew production technique. Otherwise, traditional toxicological test should be performed for product safety evaluation. | | | |
|